Abstract
Introduction Medical devices play a crucial role in promoting public health. However, there is a disparity in the availability and readiness of medical device regulations in Resource-Limited Settings (RLS) compared to the global average. We conducted a study to explore the medical device regulation landscape and stakeholder perceptions in Zimbabwe.
Methodology Between June and November 2022, we administered questionnaires to representatives of the Medicines Control Authority of Zimbabwe (MCAZ), the Medical Laboratory and Clinical Scientists Council of Zimbabwe (MLCScCZ), and the National Microbiology Reference Laboratory (NMRL). We also conducted semi-structured interviews with 12 national-level critical stakeholders from these institutions to understand the current status of medical device regulations and the relationships between them. Additionally, we interviewed regulators from the South African Health Products Regulatory Authority, Tanzania, and World Health Organisation to learn about best practices in transitioning to medical device regulations. We used a thematic approach and an inductively developed common coding framework to analyse emerging themes.
Results Our findings indicate that the current legal framework needs to be revised to regulate medical devices effectively, as it does not specify the institution(s) responsible for regulating them. While the MCAZ regulates condoms and gloves, the MLCScCZ coordinates with the NMRL to register In Vitro Diagnostic Medical Devices for priority diseases. Other medical devices are not regulated. Furthermore, conformity assessments for product registration are not proportional to the risk classification of medical devices, and post-market surveillance activities are ineffective. Stakeholders recognise the need to collaborate and improve the regulation of medical devices.
Conclusion Zimbabwe must improve its regulatory framework for medical devices to ensure that safe medical devices of acceptable quality and performance are accessible. A solid legal foundation is necessary for harmonisation and reliance practices to reduce the regulatory burden on economic operators and ease the workload on regulators.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the Medical Research Council of Zimbabwe (MRCZ/A/2900).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
